RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals

RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals
NeuroPace Inc RNS study results

NeuroPace Inc has released the results of its three year post approval study on the RNS System, now published in Neurology.

The findings suggest that the RNS System is driving a shift in the standard of care for patients, highlighting substantial improvements in life altering outcomes and confident care delivery. NeuroPace Inc expects these data to inform clinicians and support broader adoption of its neurostimulation technology. Additional safety information and access to the publication are provided directly by the company.

NeuroPace previously released NAUTILUS Study results on neuromodulation for drug-resistant idiopathic generalized epilepsy at the 2026 AAN Annual Meeting, according to company disclosures. The company reported advances in this area of treatment in data highlighted at the conference. Detailed findings from the NAUTILUS Study were also presented in a separate release.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.